Looking at the share count, it appears Cor/Resp will be nearly tapped out, assuming the new $2.5 mil financing is fully taken by the financing entity. According to Slide 31 from Dr. Manuso's recent presentation, as of Sept. 30 2915 the total shares outstanding and otherwise pledged for options/warrants is 953,402,000, so just under 1 bil shares.
By my calculations the new $2.5 mil financing will consume approx 113 mil shares assuming all tranches are taken and are priced similarly to the first $100 K tranche (at 0.02218). Adding in the 2 warrants/share brings the total shares consumed to approx 339 mil. So added to the 953 mil shares the grand total comes to approx 1.292 billion shares.
There are 1.4 bil shares authorized, in which case only approx 108 mil shares will remain available.
So... it looks like it will soon be time to raise the authorized shares again. Personally the dilution doesn't bother me since I'm not long the stock and only follow it out of general interest and for 'old times' sake. I figure a reverse split will eventually happen, which is fairly common with micro cap bios, which will bring the share structure back down to reasonable levels. I mainly just want to see Ampakines have another chance in the clinic since we've already seen that THEY WORK well in upregulating respiratory drive and also in cognitive enhancement. Anything that works deserves a full and fair chance in clinical trials.
